We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.44%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$855M
AUM Growth
-$19.9M
Cap. Flow
-$111M
Cap. Flow %
-12.98%
Top 10 Hldgs %
29.46%
Holding
101
New
12
Increased
17
Reduced
38
Closed
8

Top Buys

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$11.2M
2
ABMD
Abiomed Inc
ABMD
+$9.03M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.67M
4
EXAS
Exact Sciences
EXAS
+$8.51M
5
MGNX icon
MacroGenics
MGNX
+$7.35M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.1M
2
INCY icon
Incyte
INCY
+$13.5M
3
CELG
Celgene Corp
CELG
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$12.4M
5
EXEL icon
Exelixis
EXEL
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.64%
2 Technology 0.15%
3 Energy 0.14%
4 Financials 0.1%
5 Communication Services 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
76
DELISTED
Adverum Biotechnologies
ADVM
$627K 0.07%
11,967
– –
XOM icon
77
ExxonMobil
XOM
$659B
$494K 0.06%
6,111
– –
CVX icon
78
Chevron
CVX
$380B
$460K 0.05%
3,733
– –
VIRX
79
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$458K 0.05%
10,778
– –
DIS icon
80
Walt Disney
DIS
$178B
$387K 0.05%
3,483
– –
QCOM icon
81
Qualcomm
QCOM
$172B
$369K 0.04%
6,476
– –
IBM icon
82
IBM
IBM
$222B
$347K 0.04%
2,574
– –
MSFT icon
83
Microsoft
MSFT
$3.78T
$340K 0.04%
2,887
– –
BUD icon
84
AB InBev
BUD
$163B
$318K 0.04%
3,788
– –
JHG
85
DELISTED
Janus Henderson
JHG
$295K 0.03%
11,828
– –
F icon
86
Ford
F
$55.9B
$285K 0.03%
32,405
– –
WFC icon
87
Wells Fargo
WFC
$265B
$283K 0.03%
5,858
– –
JPM icon
88
JPMorgan Chase
JPM
$950B
$278K 0.03%
2,747
– –
HAL icon
89
Halliburton
HAL
$27.9B
$270K 0.03%
9,221
– –
GEN icon
90
Gen Digital
GEN
$17.7B
$224K 0.03%
+9,734
New +$212K
PFE icon
91
Pfizer
PFE
$154B
$213K 0.02%
5,279
– –
GOOGL icon
92
Alphabet (Google) Class A
GOOGL
$4.34T
$209K 0.02%
+3,560
New +$201K
CMRX
93
DELISTED
Chimerix, Inc.
CMRX
$145K 0.02%
68,832
-157,248
-70% -$358K
BIIB icon
94
Biogen
BIIB
$30.7B
– –
-60,000
Closed -$18.1M
GILD icon
95
Gilead Sciences
GILD
$165B
– –
-188,200
Closed -$11.8M
LH icon
96
Labcorp
LH
$25.9B
– –
-12,804
Closed -$1.39M
MD icon
97
Pediatrix Medical
MD
$2.12B
– –
-124,674
Closed -$4.11M
ADMS
98
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-159,924
Closed -$1.37M
PTLA
99
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-241,964
Closed -$4.72M
ONCE
100
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-88,302
Closed -$3.46M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rhenman & Partners Asset Management held 101 positions worth $855M, down 2.3% from $875M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $111M in Q1 2019, closing 8 positions and reducing 38 holdings. Its most notable exit was Biogen, an estimated $18.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Technology and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Exact Sciences worth $8.66M.

  • Rhenman & Partners Asset Management's largest Q1 2019 buy was Exact Sciences: 100,000 shares worth $8.66M.
  • Rhenman & Partners Asset Management added most to LivaNova in Q1 2019, an estimated $11.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2019 reduction was Incyte, cutting an estimated $13.5M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q1 2019, selling an estimated $18.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $855M portfolio in Q1 2019.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 8 in Q1 2019.
  • Rhenman & Partners Asset Management's portfolio value fell 2.3% quarter-over-quarter to $855M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2019, filed 11 Apr 2019.